MEDITRUST HEALTH HKEX IPO Application Lapsed, China’s Largest Diversified Pharmaceutical Payment Platform
NewTimeSpace News: The listing application submitted by Shanghai MediTrust Health Technology Group Co., Ltd. to HKEX on 16 January 2026 has lapsed following the expiration of the six-month timeline. Goldman Sachs, CICC and HSBC served as the original joint sponsors.
The Company is China’s largest diversified pharmaceutical payment platform. It strives to address financing and payment challenges faced by patients, insurance companies and pharmaceutical manufacturers, and advance the transformation of China’s medical payment system. Per Frost & Sullivan research, the Company secured the leading position measured by the number of partnered domestic pharmaceutical firms within the innovative smart medicine solution market, and also ranked first in the innovative smart health insurance solution market based on the volume of processed commercial health insurance policies.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHINARES PHARMA (03320.HK): Unit completes 2026 bond issue at 1.48%
- CHINARES PHARMA (03320.HK): Pre-bid process starts on unit share issue
- CHI MER LAND (00978.HK): Acquires remaining 50% of Foshan Yiyun
- ESTUN (02715.HK): Zhu Zhangxing named CFO as Wu Kan steps down
- INNOSCIENCE (02577.HK): Trustee buys 2.25m more H shares
